全文获取类型
收费全文 | 199119篇 |
免费 | 2588篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 1297篇 |
儿科学 | 7381篇 |
妇产科学 | 3592篇 |
基础医学 | 20144篇 |
口腔科学 | 1975篇 |
临床医学 | 15903篇 |
内科学 | 35009篇 |
皮肤病学 | 1093篇 |
神经病学 | 18937篇 |
特种医学 | 9441篇 |
外科学 | 30651篇 |
综合类 | 2477篇 |
一般理论 | 26篇 |
预防医学 | 20866篇 |
眼科学 | 3157篇 |
药学 | 11180篇 |
1篇 | |
中国医学 | 679篇 |
肿瘤学 | 17978篇 |
出版年
2023年 | 193篇 |
2022年 | 304篇 |
2021年 | 712篇 |
2020年 | 469篇 |
2019年 | 645篇 |
2018年 | 22558篇 |
2017年 | 17820篇 |
2016年 | 20023篇 |
2015年 | 1657篇 |
2014年 | 1665篇 |
2013年 | 2163篇 |
2012年 | 8865篇 |
2011年 | 22969篇 |
2010年 | 19805篇 |
2009年 | 12466篇 |
2008年 | 21100篇 |
2007年 | 23327篇 |
2006年 | 2225篇 |
2005年 | 3733篇 |
2004年 | 4857篇 |
2003年 | 5694篇 |
2002年 | 3666篇 |
2001年 | 417篇 |
2000年 | 524篇 |
1999年 | 324篇 |
1998年 | 411篇 |
1997年 | 364篇 |
1996年 | 245篇 |
1995年 | 212篇 |
1994年 | 217篇 |
1993年 | 161篇 |
1992年 | 108篇 |
1991年 | 165篇 |
1990年 | 191篇 |
1989年 | 151篇 |
1988年 | 98篇 |
1987年 | 84篇 |
1986年 | 68篇 |
1985年 | 77篇 |
1984年 | 85篇 |
1983年 | 92篇 |
1982年 | 94篇 |
1981年 | 48篇 |
1980年 | 90篇 |
1979年 | 37篇 |
1976年 | 32篇 |
1974年 | 41篇 |
1938年 | 60篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
961.
在皮损区拔罐,然后外涂中药治疗白癜风患者30例,对照组予西药治疗,3个疗程后,治疗组总有效率96.7%,对照组总有效率76.7%.治疗组疗效好于对照组(P<0.05). 相似文献
962.
毛遐先 《针灸推拿医学(英文版)》2004,2(3):20-21
取双侧肾俞、足三里和曲池,进行温针,并配合内服中药治疗类风湿性关节炎患者30例,以西药常规治疗30例为对照.治疗3个月后,两组有效率分别为86.7%和60.0%,疗效差异有统计意义(P<0.05). 相似文献
963.
杨鹏飞 《针灸推拿医学(英文版)》2004,2(3):37-39
目的:观察推拿结合经脉治疗仪治疗肩周炎的疗效.方法:观察组采用推拿结合日本产SSP经脉治疗仪治疗肩周炎患者35例.对照组单纯用经脉治疗仪治疗肩周炎患者30例.结果:观察组与对照组对肩周炎的治疗都有一定效果.但观察组的治愈率与对照组相比有明显差距(P<0.01),观察组对肩周炎的治愈率明显高于对照组.结论:经脉治疗仪结合推拿是治疗肩周炎的一种有效方法. 相似文献
964.
叶建国 《针灸推拿医学(英文版)》2004,2(3):40-42
应用一指禅手法为主治疗25例胸痹患者,结果显示推拿对胸痹患者的各种临床症状均有缓解作用,治愈10例,好转14例,无效1例. 相似文献
965.
目的:评价单一穴位治疗急性腰扭伤的治疗效果.方法:根据统一的诊断标准,在多个临床中心进行随机对照研究.全部病例320例经随机数字表法分为针刺后溪穴观察组和针刺腰痛点对照组.对患者的疼痛程度分别由医师和患者进行评分.结果:治疗2个疗程后,观察组和对照组近期有效率分别为89.4%和82.5%,远期有效率分别为95.6%和93.5%.经Ridit分析,近期疗效差异有统计意义(P<0.05),远期疗效差异无统计意义(P>0.05).结论:针刺单一穴位治疗急性腰扭伤疗效确切,取穴简便,后溪穴疗效好于腰痛点. 相似文献
966.
Thomas Martin Sandra R?ddiger Ralf Kurek Thomas Dannenberg Oliver Eckart Christos Kolotas Reinhard Heyd Bernd Rogge Dimos Baltas Ulf Tunn Nikolaos Zamboglou 《Radiotherapy and oncology》2004,71(1):35-41
PURPOSE: To evaluate treatment outcome of 3D conformal high dose rate (HDR) brachytherapy and external beam irradiation (EBRT) combined with temporary androgen deprivation for patients with localized prostate cancer. PATIENTS AND METHODS: Between January 1997 and September 1999 we treated 102 patients with stage T1-3 N0 M0 prostate cancer. Stage T1-2 was found in 71, T3 in 31 patients. Median pretreatment PSA level was 15.3 ng/ml. After ultrasound-guided transrectal implantation of four afterloading needles, CT based 3D brachytherapy planning was performed. All patients received four HDR implants using a reference dose per implant of 5 or 7Gy. Time between each implant was 14 days. After brachytherapy EBRT followed up to 39.6 or 45.0 Gy. All patients received temporary androgen deprivation, starting 2-19 months before brachytherapy, ending 3 months after EBRT. RESULTS: Median follow-up was 2.6 years (range 2.0-4.1 years). Actuarial biochemical control rate was 87% at 2 years and 82% at 3 years. In 14 patients we noted biochemical failure, in five patients clinical failure. Overall survival was 90%, disease specific survival 98.0% at 3 years. Acute grade 3 toxicity occurred in 4%, late grade 3 toxicity in 5%. One patient developed a prostatourethral-rectal fistula as late grade 4 toxicity. The conformal quality of 300 HDR implants was analyzed using dose volume histograms. CONCLUSIONS: 3D conformal HDR brachytherapy and EBRT combined with temporary androgen deprivation is an effective treatment modality for prostate cancer with minimal associated toxicity and encouraging biochemical control rates after a median follow-up of 2.6 years. 相似文献
967.
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. 总被引:4,自引:0,他引:4
Jennifer A Low Arlene W Berman Seth M Steinberg David N Danforth Marc E Lippman Sandra M Swain 《Journal of clinical oncology》2004,22(20):4067-4074
PURPOSE: To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy. PATIENTS AND METHODS: Between 1980 and 1988, 107 patients with stage III breast cancer were prospectively enrolled for study at the National Cancer Institute and stratified by whether or not they had features of inflammatory breast cancer (IBC). Patients were treated to best response with cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, and hormonal synchronization with conjugated estrogens and tamoxifen. Patients with pathologic complete response received definitive radiotherapy to the breast and axilla, whereas patients with residual disease underwent mastectomy, lymph node dissection, and radiotherapy. All patients underwent six additional cycles of adjuvant chemotherapy. RESULTS: OS and EFS were obtained with a median live patient follow-up time of 16.8 years. The 46 IBC patients had a median OS of 3.8 years and EFS of 2.3 years, compared with 12.2 and 9.0 years, respectively, in stage IIIA breast cancer patients. Fifteen-year OS survival was 20% for IBC versus 50% for stage IIIA patients and 23% for stage IIIB non-IBC. Pathologic response was not associated with improved survival for stage IIIA or IBC patients. Presence of dermal lymphatic invasion did not change the probability of survival in clinical IBC patients. CONCLUSION: Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patients have a poor long-term outlook. 相似文献
968.
Wen Qing Yang Xueqing Lun Cheryl Ann Palmer M Elizabeth Wilcox Huong Muzik Zhong Qiao Shi Richard Dyck Matt Coffey Brad Thompson Mark Hamilton Sandra G Nishikawa Penny M A Brasher Kevin Fonseca David George N Berry Rewcastle Randal N Johnston Doug Stewart Patrick W K Lee Donna L Senger Peter A Forsyth 《Clinical cancer research》2004,10(24):8561-8576
PURPOSE: Human reovirus type 3 has been proposed to kill cancer cells with an activated Ras signaling pathway. The purpose of this study was to investigate the efficacy of reovirus in immunocompetent glioma animal models and safety/toxicity in immunocompetent animals, including nonhuman primates. EXPERIMENTAL DESIGN: Racine glioma cells 9L and RG2 were implanted s.c. or intracranially in Fisher 344 rats with or without reovirus antibodies, followed by treatment of reovirus. To study whether reovirus kills contralateral tumors in the brain and to determine viral distribution, we established an in situ dual tumor model followed by reovirus intratumoral inoculation only into the ipsilateral tumor. To evaluate neurotoxicity/safety of reovirus, Cynomolgus monkeys and immunocompetent rats were given intracranially with reovirus, and pathological examination and/or behavioral studies were done. Viral shedding and clinical biochemistry were systematically studied in monkeys. RESULTS: Intratumorally given reovirus significantly suppressed the growth of both s.c. and intracranially tumors and significantly prolonged survival. The presence of reovirus-neutralizing antibodies did not abort the reovirus' antitumor effect. Reovirus inhibited glioma growth intracranially in the ipsilateral but not the contralateral tumors; viral load in ipsilateral tumors was 15 to 330-fold higher than the contralateral tumors. No encephalitis or behavioral abnormalities were found in monkeys and rats given reovirus intracranially. No treatment-related clinical biochemistry changes or diffuse histopathological abnormality were found in monkeys inoculated intracranially with Good Manufacturing Practice prepared reovirus. Microscopic changes were confined to the region of viral inoculation and were dose related, suggesting reovirus intracranially was well tolerated in nonhuman primates. CONCLUSIONS: These data show the efficacy and safety of reovirus when it is used in the treatment of gliomas in immunocompetent hosts. Inoculation of reovirus into the brain of nonhuman primates did not produce significant toxicities. 相似文献
969.
Alcohol exposure and breast cancer: results of the women's contraceptive and reproductive experiences study. 总被引:2,自引:0,他引:2
Jill A McDonald Michele G Mandel Polly A Marchbanks Suzanne G Folger Janet R Daling Giske Ursin Michael S Simon Leslie Bernstein Brian L Strom Sandra A Norman Kathleen E Malone Linda K Weiss Ronald T Burkman Anita L Weber Robert Spirtas 《Cancer epidemiology, biomarkers & prevention》2004,13(12):2106-2116
OBJECTIVES: To explore associated biological outcomes and clarify the role of timing of exposure in the alcohol-breast cancer relationship.METHODS: In a population-based study of 4,575 women ages 35 to 64 years diagnosed with invasive breast cancer between 1994 and 1998 and 4,682 controls, we collected details of lifetime alcohol use and factors that could confound or modify the alcohol-breast cancer relationship. We used conditional logistic regression to compute the odds of breast cancer among drinkers relative to nondrinkers at all ages and at ages 35 to 49 and 50 to 64 years separately.RESULTS: Recent consumption (at reference age minus two) of >/=7 drinks per week was associated with increased risk [odds ratio (OR), 1.2; 95% CI, 1.01-1.3] and evidence of dose response was observed. Most of the excess was observed among women ages 50-64 years (OR 1.3; 95% CI, 1.1-1.6), although the test for age interaction was not statistically significant. Exposure later in life seemed more important than early exposure. Excess breast cancer associated with recent consumption was restricted to localized disease. When outcome was examined according to tumor hormone receptor status, highest risks were observed for estrogen receptor-positive/progesterone receptor-negative tumors (OR 1.6; 95% CI, 1.2-2.3).CONCLUSIONS: The effect of timing of alcohol exposure on breast cancer risk is complicated and will require additional study focused on this one issue. Further work is needed to explain how alcohol exposure, sex hormones, and tumor receptor status interact. 相似文献
970.
卵巢癌高频转移细胞模型中nm23-H1基因表达的相关性研究 总被引:1,自引:0,他引:1
目的 筛选高频转移卵巢恶性肿瘤细胞,研究不同转移潜能的细胞和nm23的相关性。方法 通过反复动物接种和体外培养,观察动物肺转移状况,筛选高频转移细胞株,比较原发肿瘤和转移肿瘤的特征,并应用Northera-blot方法测定各类肿瘤细胞nm23 mRNA表达水平。结果 8株卵巢恶性肿瘤细胞中4株有较高转移潜能。多次培养接种可筛选出高频转移细胞亚群。测定各类细胞nm23 mRNA表达水平与肿瘤转移特性呈负相关。结论 由基因分子水平决定的肿瘤转移趋势在不同肿瘤种类及细胞亚群中有明显差异;卵巢癌中nm23 mRNA和蛋白的表达与其转移能力的降低有密切关系,可作为判定卵巢癌预后的敏感指标。 相似文献